<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151289">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01821989</url>
  </required_header>
  <id_info>
    <org_study_id>moos80</org_study_id>
    <nct_id>NCT01821989</nct_id>
  </id_info>
  <brief_title>Oral Lactoferrin Supplementation for Prevention of Sepsis in Preterm Neonate</brief_title>
  <official_title>Oral Lactoferrin Supplementation for Prevention of Sepsis in Preterm Neonate.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mooselmokadem</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mooselmokadem</source>
  <oversight_info>
    <authority>Egypt: Ain Shams university</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:

      Orally ingested lactoferrin has effects on promotion of growth and differentiation of the
      immature gut; also it has immunomodulatory properties, so it will prevent serious infections
      in preterm infants.

      The aim of the study is to:

        -  Evaluate the effectiveness of oral lactoferrin in prevention of neonatal sepsis.

        -  Compare two dose regiment of lactoferrin supplementation.

        -  Study effect of lactoferrin supplementation on serum iron stores.

      It is a prospective, randomized, double blind, placebo-controlled study, it will include 180
      preterm neonates admitted to the Neonatal Intensive Care Units of of Ain Shams University
      Hospitals and Manshiet El Bakry Hospital.

      •Group A: Who will receive oral lactoferrin supplementation in a dose of 100 mg/day.

      •Group B: Who will receive oral lactoferrin supplementation in a dose of 150 mg/kg/ twice
      daily.

      •Group C (Controls): Who match the subjected neonates, will receive placebo in form of
      distilled water.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Blood culture</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete blood count with differential leucocytic count.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>C reactive protein quantitative assay</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Neonatal Sepsis</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lactoferrin,dose of 100 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactoferrin, dose of 150 mg/kg/ twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Receive placebo in form of distilled water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactoferrin</intervention_name>
    <description>dose of 100 mg/day</description>
    <arm_group_label>Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactoferrin</intervention_name>
    <description>dose of 150 mg/kg/ twice daily</description>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>in form of distilled water</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Neonates with a birth weight between 500g and 2500g.

          2. Neonates with a ≤ 36 weeks of gestation counting from the first day of the Last
             Menstrual Period.

          3. Preterm neonates born in, or referred to the Neonatal Intensive Care Units of one of
             the participating hospitals in the first 48 hours of life.

        Exclusion Criteria:

          1. Neonates with underlying gastrointestinal problems that prevent oral intake.

          2. Neonates with predisposing conditions that profoundly affect growth and development
             (chromosomal abnormalities, structural brain anomalies, severe congenital
             abnormalities).

          3. Neonates with a family background of cow milk allergy.

          4. Neonates who will not have the chance to complete the study time (who will be
             referred to another hospitals).

          5. Neonates whose parents decline to participate.

          6. Neonates with early onset sepsis.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mostafa AM Elmokadem, Master</last_name>
    <phone>01110857100</phone>
    <phone_ext>02</phone_ext>
    <email>drmooselmokadem@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <state>Abassia</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>March 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mooselmokadem</investigator_affiliation>
    <investigator_full_name>Mostafa El-Mokadem</investigator_full_name>
    <investigator_title>neonatologist</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
